These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 17045935

  • 1. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
    Ray JE, Keogh AM, McLachlan AJ.
    J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
    [Abstract] [Full Text] [Related]

  • 2. Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors.
    Ray JE, Keogh AM, McLachlan AJ, Akhlaghi F.
    J Heart Lung Transplant; 2003 Jul; 22(7):715-22. PubMed ID: 12873538
    [Abstract] [Full Text] [Related]

  • 3. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259
    [Abstract] [Full Text] [Related]

  • 4. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
    Aros CA, Schneider HO, Flores CA, Ardiles LG, Alruiz PA, Jerez V, Mezzano SA.
    Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
    [Abstract] [Full Text] [Related]

  • 5. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S, Vareesangthip K, Ong-ajyooth L.
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [Abstract] [Full Text] [Related]

  • 6. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P, Kocher A, Neuhauser P, Sarahrudi K, Seweryn J, Wisser W, Klepetko W.
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy.
    Lück R, Böger J, Kuse E, Klempnauer J, Nashan B.
    Liver Transpl; 2004 May; 10(5):686-91. PubMed ID: 15108262
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB, Ruttmann E, Geltner C, Bucher B, Nagiller J, Laufer G, Mueller LC.
    Clin Transplant; 2008 May; 22(1):35-40. PubMed ID: 18217903
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S, Saint-Marcoux F, Rousseau A, Zhang D, Leroy V, Marquet P, Jacqz-Aigrain E.
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [Abstract] [Full Text] [Related]

  • 14. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole.
    Videla C, Vega J, Borja H.
    Transplant Proc; 2005 Apr; 37(3):1574-6. PubMed ID: 15866677
    [Abstract] [Full Text] [Related]

  • 15. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U, Ullrich S, Roskos M, Misselwitz J.
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
    [Abstract] [Full Text] [Related]

  • 17. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA, Veinot JP, Williams K, Haddad H, Baker A, Donaldson J, Pugliese C, Struthers C, Masters RG, Hendry PJ, Mesana T.
    Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
    [Abstract] [Full Text] [Related]

  • 18. Limitations of C2 monitoring in renal transplant recipients.
    Einecke G, Schütz M, Mai I, Fritsche L, Giessing M, Glander P, Neumayer HH, Budde K.
    Nephrol Dial Transplant; 2005 Jul; 20(7):1463-70. PubMed ID: 15840681
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ, Strong DK, Keown PA.
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.